Evidence map›Paper›PMID 36780304›Full record

ArticleOncotarget2023

Unveiling the non-canonical functions of EZH2 in prostate cancer.

Yang Yi, Yanqiang Li, Kaifu Chen, Qi Cao

Open access · diamondAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yang Yi
Yanqiang Li
Kaifu Chen
Qi Cao
Northwestern Memorial Hospital · USNorthwestern University · US

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 1995 to 2013
$31.3M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
A non-canonical role for EZH2 in rRNA methtlationR01CA256741 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CAO, QI · 2021 to 2025
$2.1M
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancerR01CA208257 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CAO, QI · 2017 to 2022
$1.8M
Bioinformatics Techniques to Analyze Dynamic Changes of 3D GenomeR01GM138407 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI CHEN, KAIFU · 2022 to 2025
$1.8M
Computational epigenetics modeling of cell identity genesR01GM125632 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU · 2018 to 2021
$1.4M
NCI NIH HHS P50 CA069568NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA208257NCI NIH HHS R01 CA256741NIGMS NIH HHS R01 GM125632NIGMS NIH HHS R01 GM138407
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHumansMaleTranscription FactorsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanTranscription FactorsCDCA8E2F1EZH2FBLprostate cancer

Identifiers

PMID36780304
PMCPMC9924823
OpenAlexW4320036052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.